18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease

Research output: Contribution to journalArticle

Abstract

To elucidate the relationship between cerebrospinal fluid (CSF) total-tau (T-tau) and phosphorylated tau (P-tau) with the tau PET ligand 18F-AV-1451 in Alzheimer's disease (AD), we examined 30 cognitively healthy elderly (15 with preclinical AD), 14 prodromal AD, and 39 AD dementia patients. CSF T-tau and P-tau were highly correlated (R = 0.92, P < 0.001), but they were only moderately associated with retention of 18F-AV-1451, and mainly in demented AD patients. 18F-AV-1451, but not CSF T-tau or P-tau, was strongly associated with atrophy and cognitive impairment. CSF tau was increased in preclinical AD, despite normal 18F-AV-1451 retention. However, not all dementia AD patients exhibited increased CSF tau, even though 18F-AV-1451 retention was always increased at this disease stage. We conclude that CSF T-tau and P-tau mainly behave as biomarkers of "disease state", since they appear to be increased in many cases of AD at all disease stages, already before the emergence of tau aggregates. In contrast, 18F-AV-1451 is a biomarker of "disease stage", since it is increased in clinical stages of the disease, and is associated with brain atrophy and cognitive decline.

Details

Authors
Organisations
External organisations
  • Skåne University Hospital
  • University of Texas Health Science Centre
  • Sahlgrenska University Hospital
  • Sahlgrenska Academy
  • University College London
  • University of Gothenburg
  • University of California, San Francisco
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Neurology

Keywords

  • Alzheimer, Biomarker, Cerebrospinal fluid, Positron emission tomography, Tau
Original languageEnglish
Pages (from-to)1212-1223
JournalEMBO Molecular Medicine
Volume9
Publication statusPublished - 2017
Publication categoryResearch
Peer-reviewedYes